9th RNA-Targeted Drug Discovery & Development Summit

About this event

RNA-targeting small molecules are rapidly gaining therapeutic traction, underscored by clinical advances including ReviR Therapeutics first participant dosed in a Phase 1 study of RTX-117 and Remix Therapeutics reporting positive Phase 1/2 data for REM-422. Building on the clinical validation of splice modulation, the field is progressing across direct RNA binding, RNA degradation, covalent translation inhibition, epitranscriptomic regulation and condensate biology, establishing RNA-targeted small molecules as an increasingly credible route to modulate disease biology once considered beyond the reach of conventional protein-targeted strategies.

With scientific innovation at the core of this momentum, the 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston this November as the industry’s only dedicated forum focused exclusively on RNA-targeted small molecules. Bringing together leaders from pioneering biotechs, major pharma and expert academia, including PTC Therapeutics, Remix Therapeutics, ReviR Therapeutics, AstraZeneca, Sanofi, Atomic AI, Syrna Therapeutics, Dewpoint Therapeutics, EPICS Therapeutics, Ribonaut Therapeutics and Ribometrix, the summit will deliver the latest data, practical discovery strategies and collaborative discussion shaping the future of RNA-targeted therapeutics.

With a refreshed agenda spanning functional RNA target selection, structure-guided design, productive chemical space, emerging RNA-targeting technologies, and translational considerations, this forum reaffirms its position as the go-to meeting for connecting the scientific and strategic decisions needed to progress RNA-targeted small molecules from discovery toward clinical impact.

From Hanson Wade